Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
      Description

      Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine. In this study, ADI will be combined with the well known chemotherapy cisplatin, and the safety and potential efficacy of this combination will be explored in patients with cancers that require arginine.

      Conditions
      Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
      Talk to us
      COMPLETED
      A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
      Description

      The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.

      Conditions
      Cervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])Esophageal CancerHepatocellular CarcinomaMelanoma (Uveal Melanoma Excluded)Merkel Cell CarcinomaMesotheliomaMSI-high Colorectal CancerNon-small Cell Lung Cancer (NSCLC)Ovarian CancerSquamous Cell Carcinoma of the Head and Neck (SCCHN)Small Cell Lung Cancer (SCLC)Renal Cell Carcinoma (RCC)Triple-negative Breast CancerUrothelial CarcinomaDiffuse Large B-cell Lymphoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
      Description

      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

      Conditions
      Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamousUrothelial CarcinomaRenal Cell Carcinoma, Clear CellCastration-resistant Prostate CancerOvarian Cancer, EpithelialTNBC - Triple-Negative Breast CancerColorectal Cancer
      Talk to us
      COMPLETED
      A Study of PLX2853 in Advanced Malignancies.
      Description

      The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

      Conditions
      Small Cell Lung CancerUveal MelanomaOvarian Clear Cell CarcinomaNon-Hodgkin LymphomaAdvanced MalignanciesSolid TumorDiffuse Large B Cell LymphomaFollicular Lymphoma
      Talk to us